PMID- 29204551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2095-8811 (Print)
IS  - 2589-1081 (Electronic)
IS  - 2095-8811 (Linking)
VI  - 2
IP  - 2
DP  - 2016 Jun
TI  - mTOR, metabolism, and the immune response in HPV-positive head and neck squamous 
      cell cancer.
PG  - 76-83
LID - 10.1016/j.wjorl.2016.05.010 [doi]
AB  - Extensive preclinical studies have identified mammalian target of rapamycin 
      (mTOR) activation as a frequent molecular signature underlying head and neck 
      squamous cell carcinoma (HNSCC), including the distinct clinical subtype that is 
      human papillomavirus (HPV) related, and have demonstrated the potential 
      therapeutic utility of mTOR inhibitors in the treatment of these cancers. 
      Numerous clinical studies have begun to evaluate this potential, however few have 
      selected for and fewer have focused specifically on HPV-related disease. While 
      HPV-positive (HPV+) HNSCC patients have a generally favorable prognosis, the 
      overall number of patients who suffer failed treatment, recurrent disease, 
      metastasis, and death is increasing due to the rapidly increasing incidence of 
      HPV-related cancers. In this review, we discuss the rationale for proposing the 
      adjuvant use of mTOR inhibition in the treatment of HPV+ HNSCC, highlighting the 
      interplay of virally activated mTOR signaling, cellular metabolism, and the 
      anti-tumor immune response.
FAU - Coppock, Joseph D
AU  - Coppock JD
AD  - Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, SD 57104, USA.
FAU - Lee, John H
AU  - Lee JH
AD  - Cancer Biology Research Center, Sanford Research/USD, Sioux Falls, SD 57104, USA.
AD  - Department of Otolaryngology-Head and Neck Surgery, Sanford Health, Sioux Falls, 
      SD 57105, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160720
PL  - United States
TA  - World J Otorhinolaryngol Head Neck Surg
JT  - World journal of otorhinolaryngology - head and neck surgery
JID - 101690857
PMC - PMC5698505
OTO - NOTNLM
OT  - Head and neck oropharyngeal carcinoma
OT  - Human papillomavirus
OT  - Metabolism
OT  - Rapamycin
OT  - mTOR
EDAT- 2016/07/20 00:00
MHDA- 2016/07/20 00:01
PMCR- 2016/07/20
CRDT- 2017/12/06 06:00
PHST- 2016/04/05 00:00 [received]
PHST- 2016/05/11 00:00 [accepted]
PHST- 2017/12/06 06:00 [entrez]
PHST- 2016/07/20 00:00 [pubmed]
PHST- 2016/07/20 00:01 [medline]
PHST- 2016/07/20 00:00 [pmc-release]
AID - S2095-8811(16)30015-4 [pii]
AID - 10.1016/j.wjorl.2016.05.010 [doi]
PST - epublish
SO  - World J Otorhinolaryngol Head Neck Surg. 2016 Jul 20;2(2):76-83. doi: 
      10.1016/j.wjorl.2016.05.010. eCollection 2016 Jun.